/APH.L
APH.L Stock - Alliance Pharma plc
Healthcare|Drug Manufacturers - Specialty & GenericLSE
$64.70+0.02%
+$0.01 (+0.02%) • May 13
75
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.86
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.97
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $71.17
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for APH.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$64.05 – $65.35
TARGET (TP)$74.41
STOP LOSS$59.52
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.58
52W High$66.20
52W Low$24.55
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $178.84M | $180.68M | $167.42M | $163.21M | $129.80M |
| Gross Profit | $109.29M | $105.02M | $101.68M | $109.45M | $82.82M |
| Gross Margin | 61.1% | 58.1% | 60.7% | 67.1% | 63.8% |
| Operating Income | $-8,098,000 | $-38,442,000 | $28.43M | $21.57M | $16.32M |
| Net Income | $-10,729,000 | $-33,136,000 | $-21,208,000 | $7.32M | $8.03M |
| Net Margin | -6.0% | -18.3% | -12.7% | 4.5% | 6.2% |
| EPS | $-0.02 | $-0.06 | $0.00 | $0.01 | $0.02 |
Company Overview
Alliance Pharma plc operates as a pharmaceutical company in Europe, the Middle East, Africa, the Asia Pacific, China, and the Americas. The company acquires, markets, and distributes consumer healthcare and prescription medicine products. It holds the marketing rights of approximately 80 consumer healthcare and prescription medicine products. The company also offers medical devices, food supplements, and cosmetics. Alliance Pharma plc provides its products under the Aloclair, Anbesol, Asthon and Parsons, Atopiclair, Forceval, Hydromol, Kelo-cote, Macushield, Vamousse, Nizoral, and Amberen brand names. The company was founded in 1996 and is headquartered in Chippenham, the United Kingdom.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
APH.LBeat Rate
0%
Last 7 quarters
Avg Surprise
-145.0%
EPS vs Estimate
Beats / Misses
0/7
Last 12 quarters
Latest EPS
$-0.03
Q2 2025
EPS Surprise History
Q2 21
-43.8%
$0.02vs$0.03
Q4 21
-105.9%
$-0.00vs$0.03
Q2 22
-4.2%
$0.02vs$0.03
Q1 23
-250.2%
$-0.02vs$0.01
Q3 23
-52.9%
$0.01vs$0.02
Q2 24
-344.0%
$-0.07vs$0.03
Q3 24
No data
Q2 25
-213.9%
$-0.03vs$0.03
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Sep 29, 2025 | — | — | — | — |
Q2 2025 | Apr 8, 2025 | $0.03 | $-0.03 | -213.9% | ✗ MISS |
Q3 2024 | Sep 30, 2024 | — | $0.01 | — | — |
Q2 2024 | May 8, 2024 | $0.03 | $-0.07 | -344.0% | ✗ MISS |
Q3 2023 | Sep 26, 2023 | $0.02 | $0.01 | -52.9% | ✗ MISS |
Q1 2023 | Mar 21, 2023 | $0.01 | $-0.02 | -250.2% | ✗ MISS |
Q2 2022 | Jun 30, 2022 | $0.03 | $0.02 | -4.2% | ✗ MISS |
Q4 2021 | Dec 31, 2021 | $0.03 | $-0.00 | -105.9% | ✗ MISS |
Q2 2021 | Jun 30, 2021 | $0.03 | $0.02 | -43.8% | ✗ MISS |
Q4 2020 | Dec 31, 2020 | — | $0.02 | — | — |
Q3 2020 | Sep 22, 2020 | — | $-0.00 | — | — |
Q4 2019 | Dec 31, 2019 | — | $0.02 | — | — |
Q2 2019 | Jun 30, 2019 | — | $0.02 | — | — |
Q4 2018 | Dec 31, 2018 | — | $0.01 | — | — |
Q2 2018 | Jun 30, 2018 | — | $0.02 | — | — |
Q4 2017 | Dec 31, 2017 | — | $0.01 | — | — |
Q2 2017 | Jun 30, 2017 | — | $0.03 | — | — |
Q4 2016 | Dec 31, 2016 | — | $0.02 | — | — |
Q2 2016 | Jun 30, 2016 | — | $0.02 | — | — |
Q4 2015 | Dec 31, 2015 | — | $0.02 | — | — |
Latest News
Loading news...
Frequently Asked Questions about APH.L
What is APH.L's current stock price?
Alliance Pharma plc (APH.L) is currently trading at $64.70 per share. The stock has moved +0.02% today.
What is the analyst price target for APH.L?
No analyst price targets are currently available for this stock.
What sector is Alliance Pharma plc in?
Alliance Pharma plc operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. The company is traded on the LSE exchange.
What is APH.L's market cap?
Alliance Pharma plc has a market capitalization of $0.35 billion, making it a small-cap company.
Does APH.L pay dividends?
No, Alliance Pharma plc does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARIX.L
Arix Bioscience plc
$142.00
Mkt Cap: $18.4B
BMK.L
Benchmark Holdings plc
$22.05
Mkt Cap: $13.6B
CEL.L
Celadon Pharmaceuticals Plc
$13.40
Mkt Cap: $0.9B
HELD.L
Hellenic Dynamics Plc
$0.95
Mkt Cap: $0.1B
INS.L
Instem plc
$829.00
Mkt Cap: $19.9B
MGP.L
Medica Group Plc
$212.00
Mkt Cap: $26.8B
MXC.L
MGC Pharmaceuticals Limited
$21.20
Mkt Cap: $0.9B
MXCT.L
MaxCyte, Inc.
$147.69
Mkt Cap: $15.7B
RGT.L
Argent BioPharma Limited
$6.00
Mkt Cap: $0.4B
SMD.L
Spectral MD Holdings, Ltd.
$58.00
Mkt Cap: $8.0B
Explore stocks similar to APH.L for comparison